This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Cheryl Lee, and today we'll be discussing a topic that has continued to be controversial. I'm ...

Please provide your email address to receive an email when new articles are posted on . Robotic-assisted cystectomy demonstrated comparable 2-year PFS to open cystectomy among patients with bladder ...

How does robot-assisted radical cystectomy compare with traditional open radical cystectomy for management of patients with bladder cancer? To answer this question, the authors of a study published in ...

In a randomized study, patients who underwent robotic-assisted and open radical cystectomy had similar 2-year progression survival rates. Robot-assisted radical cystectomy (RC) for invasive bladder ...

The impact of pathologic downstaging with neoadjuvant chemotherapy on survival of patients with muscle-invasive bladder cancer. A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 ...

In the past decade there has been a rapid expansion of the use of robotic assistance during surgery that involves minimally invasive approaches. In the United Kingdom, robot-assisted radical ...

A randomized controlled trial has shown that short-term outcomes following robot-assisted radical cystectomy compare favorably with those of open surgery. To date, a lack of hard clinical evidence to ...

Please provide your email address to receive an email when new articles are posted on . Use of robot-assisted vs. open radical cystectomy led to a significantly increased number of days alive and out ...

Robot-assisted and open radical cystectomy are associated with similar 90-day complication rates, health-related quality of life, and clinical outcomes, according to a recent real-world study.

Quality of life in patients undergoing paclitaxel-based second-line treatment of urothelial cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include ...

"The main strength of this study is the use of a nationwide population-based cohort encompassing nearly all patients with bladder cancer undergoing RC over 8 years, with detailed clinicopathological, ...